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ABSTRACT 
Introduction: A Drug-drug interaction (DDI) is a decrease or increase in the pharmacological or clinical response to the 
administration of two or more drugs that are different from the anticipated response they initiate when individually administered.  
Objectives: To assess the prevalence and factors associated with potential DDIs among adult inpatients admitted to the medical 
wards of a tertiary teaching Hospital in Ethiopia. 
Methods: A retrospective cross-sectional study design was employed on adult Patients who were admitted to the medical ward in 
one year period. A total of 384patients’ medical records were checked for a possible DDI using Micromedex DrugReax® drug 
interaction database and analyzed consecutively using SPSS version 20.0. 
Results: Among 384 adult Patients enrolled in the study, 209 (54.4%) of them had medications with at least one potential DDI in 
their prescriptions. Of the 209 potential DDI, 26.3% were with a minimum of one major potential DDI. The median number of 
potential DDI per patient was 2.2. Overall, 296 potential DDI were identified in the current study. Among 296 identified potential 
drug-drug interactions, most of the interaction (49.7%) had good documentation. The number of medication prescribed per patient 
showed a significant (p< 0.001) association with the occurrence of potential DDIs. 
Conclusion: More than half of the patients’ prescription contains potentially interacting medications. This study, additionally, 
revealed that there is a significant association between potential DDIs and number of medications prescribed per patient.  
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1. INTRODUCTION 
Drug interactions are the possibility that 
pharmacological effect of one drug might be altered by 
another agent, present concurrently. It can involve 
interactions between drugs and disease, drugs and 
chemicals in the environment, drugs and nutrients, and 
drugs and drugs 
1
. Concurrently administered drugs may 
act independently, or interact with each other 
2
. Drug–
drug interaction (DDI) is thus defined as a 
pharmacological or clinical response to the 
administration of two or more drugs that are different 
from the response they initiate when individually 
administered
3
.
 
The interaction may increase or decrease the effects of 
the involved drugs and sometimes may cause 
unexpected toxicity, side effects or failure of the 
pharmacological therapy 
4
. Such DDIs can be classified 
as pharmacokinetic, pharmacodynamic and 
pharmaceutical, based on the mechanism of interaction 
1
. Clinically significant DDIs might pose a potential 
harm to Patients 
5
. Moreover, it may present with 
harmful outcomes, resulting in an estimated cost of 
more than 1 billion USD per year to governmental 
health care systems expenditure 
6
. 
A drug interaction, which is an emerging threat to public 
health 
6
, can occur within a couple of minutes or can 
take several weeks to develop 
7
. There are various 
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factors contributing factors to the occurrence of DDIs. 
This includes polypharmacy, use of non-prescription 
drugs, drug abuse and patient noncompliance 
5,8
. 
Tamblyn et al. 
9
 reported that about one-quarter of 
inappropriate drug combinations were resulted from 
contemporaneous prescribing by different physicians. 
Patient factors that increase the risk for drug interactions 
include being critically ill, age, genetic factors, renal 
function, hepatic function, alcohol consumption, 
smoking, diet, environmental factors, individual 
variations, hypoxemia, or metabolic disturbances, and 
being elderly 
5,8,10
. Some of the factors have shown 
consistent association with the presence of potential 
DDIs 
11
.  
The risk of DDI rose from 13% for Patients taking two 
medications to 82% for Patients taking seven or more 
medications 
12
. Drug interactions are considerable cause 
of adverse drug reactions (ADRs) and hospital 
admission 
13
. In some studies
14, 15
, DDIs have been 
reported to be responsible for up to 3% of 
hospitalizations. Besides, hospitalized Patients are more 
likely to be affected by these DDIs because of severe 
and multiple illnesses, co-morbid conditions, chronic 
therapeutic regimens, polypharmacy and frequent 
modification in therapy 
16
. It is imperative to determine 
the prevalence of DDIs in adult patients. Despite a very 
few studies done in Ethiopia to evaluate the potential 
DDIs, there is no enough study that shows the situation 
of Potential DDI in inpatient wards. Thus, this study 
aimed to assess the prevalence and factors associated 
with potential DDI among adult inpatients admitted to 
medical wards of a tertiary teaching Hospital in Ethiopia  
2. MATERIAL AND METHODS 
2.1. Study Settings and Design 
A retrospective cross sectional study was employed on 
Patients admitted to the medical unit of inpatient ward 
of Saint Paul’s Hospital Millennium Medical College 
(SPHMMC). SPHMMC is the second largest tertiary 
medical teaching hospital in the country which is 
located in the capital city, Addis Ababa.  It was 
inaugurated in July 1947 and equipped with 250 beds. 
The study was conducted from Mayto June 2016. 
2.2 Study Population  
All adult Patients receiving inpatient care at internal 
medicine ward of SPHMMC were the source population 
of the study and adult Patients admitted to the internal 
medicine wards from May 1, 2015 to April 30, 2016 
were considered as the study population. All Patients 
exposed to two or more concomitant drugs during their 
stay in the ward were eligible for the study.  
2.3 Sample Size and Sampling Procedure  
A single proportion formula was employed for sample 
size estimation. A total sample size of 384was estimated 
with considering the P as 0.5 at 95%CI and 5% margin 
of error. The respective patient cards were selected 
throughsystematic random sampling techniques using 
the patient admission registration catalogue as a 
sampling frame.  
2.4 Data Collection Tools  
Data was collected from the patient medical chart using 
a structured and pretested data abstraction format. The 
data was collected by the principal investigator and two 
traineddata collector nurses.  
2.5 Operational Definitions 
Contraindicated DDI: The drug-pair is contraindicated 
for concurrent use. 
Major DDI: The effects are potentially life threatening 
or capable of causing permanent damage. 
Moderate DDI: It may cause deterioration in patients’ 
clinical status and additional treatment or extension of 
hospital stay. 
Minor DDI: The effects are usually mild. 
Consequences may be bothersome or unnoticeable but 
should not significantly affect the therapeutic outcome 
17, 18
.  
Excellent Documentation: controlled studies have 
clearly established the existence of the interaction 
Good Documentation: documentation strongly 
suggests the interaction exists, but well-controlled 
studies are lacking 
Fair Documentation: available documentation is poor, 
but pharmacologic considerations lead clinicians to 
suspect the interaction exists; or, documentation is good 
for a pharmacologically similar drug 
17,18
. 
2.6 Analysis of potential DDIs 
Medications were screened for potential DDIs using 
drug interaction software, Micromedex Drug Reax® 
(Thomson Reuters Inc., 2011). Micromedex Healthcare 
Series Greenwood Village/CO). Micromedex is used to 
check and describe the type and severity of drug-drug 
interaction
19
. 
2.7 Statistical analysis 
The collected data was first checked for completeness 
then compiled, processed and analyzed using SPSS for 
Windows version 20.0. Descriptive statistics 
(frequencies, percentage, mean and standard deviation) 
were used to present counts, proportions and averages. 
Chi-squared test was used to identify potential factors 
having association with potential DDIs. 
2.8 Ethical Consideration 
Ethical clearance was obtained from Ethical Review 
Committee of the School of Pharmacy, Addis Ababa 
University as well as from the Department of Internal 
Medicine in SPHMMC. Privacy and confidentiality was 
ensured during review of patients’ chart by data 
collectors. Thus, name and address of Patients was not 
recorded in the data collection format. Moreover, the 
data collectors and the principal investigator provided 
appropriate drug information to heath care professionals 
when necessary. 
3. RESULTS 
3.1 Demographic information 
A total of 384 adult Patients were enrolled in the study. 
Among these, 193(50.2 %) of the Patients were females. 
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Patients’ age ranges from 15 to 85 years (mean age; 
41.37 16.208 years). The major diagnosis for these 
patients were renal disorder, cardiovascular disorder and 
infectious disease with a frequency of 89 (23.2%), 85 
(22.13%) and 78 (203%), respectively (Table 1). 
 
Table 1: Socio-demographic characteristics of Adult Patients admitted to Medical wards of SPHMMC, June 
2016 (N=384) 
Variable  Frequency                  
 
Percentage (%) 
Gender  
 
 
Age category (years)  
 
 
 
 
 
Co-morbidity  
 
 
Number of prescribed 
medications  per patient  
 
 
Major Diagnosis 
 
 
 
 
Male 
Female 
 
 15-24 
 25-44 
 45-64 
 ≥65 
 
Present  
Absent  
 
≤ 4  
≥5 
 
Renal disease 
Cardiovascular 
Infectious 
Gastrointestinal 
Hematologic 
Thromboembolic 
Liver 
Diabetes Mellitus 
Stroke 
Others* 
 
 
 
 
 
 
193 
191 
 
56 
178 
96 
53 
 
55 
329 
 
262 
122 
 
89 
85 
78 
32 
26 
22 
20 
14 
14 
4 
 
 
 
 
50.2 
49.8 
 
14.8 
46.4 
       25.0 
13.8 
 
14. 32 
85.68 
 
68.23 
31.77 
 
23.18 
22.13 
20.3 
8.34 
6.77 
5.73 
5.21 
3.65 
3.65 
1.04 
 
 
 
 
 
 
 
    Note:* Solid tumor (n=2), airway obstruction (n=1) and neurologic(n=1) 
 
3.2 Prevalence of Potential Drug-Drug Interactions 
In this study, a total of 296 Potential DDIs were 
identified. Among 384 adult Patients admitted in 
medical wards, 209(54.4%) of them had prescriptions 
with at least one potential DDI irrespective of how 
severe the interactions are. In majority of cases, one to 
two Potential DDIs per patient were identified with 
median of 2.2 potential DDIs per patient with a range of 
1-9 (Table 2).In the pharmacologic intervention, 101 
(26.3%), 159 (41.4%) and 33 (8.6%) interacting drug 
pairs were having major, moderate and minor severity 
potential DDIs, respectively (Table 3). 
  
Table 2: Prevalence of potential DDIs among adult Patients admitted to medical wards of SPHMMC, June 2016 
(N=209) 
Variables Frequency  
 
 
Percentage (%) 
Number of PDDIs per 
Patient 
1 
2 
3 
4 
5 
6 
7 
8 
9 
PDDIs per Patient  
mean 
 
 
 
98 
42 
27 
19 
12 
4 
3 
3 
1 
 
2.2, range (0-9) 
 
 
 
 
 
 
46.90 
20.10 
12.9 
9.10 
5.74 
1.90 
1.44 
1.44 
0.48 
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Table 3: Severity, documentation, onset and mechanisms of identified potential DDI for Patients admitted to 
medical ward of SPHMMC, 2016(n=296) 
Level Frequency 
 
 
Percentage (%) 
Severity 
    Contraindicated 
    Major 
    Moderate 
    Minor 
Documentation    
    Excellent 
    Good 
    Fair 
Onset 
    Rapid 
    Delayed 
    Non-specific 
 
 
 
2 
105 
157 
32 
 
38 
147 
111 
 
49 
116 
131 
 
0.7 
35.5 
53.0 
10.8 
 
12.8 
49.7 
37.5 
 
16.5 
39.2 
44.3 
 
3.3 Levels and mechanism of Potential DDIs 
The identified potential DDIs were categorized into 
different levels according to onset, severity, scientific 
evidence and mechanism of interaction, using the online 
drug interaction checker; Micromedex. Almost half 
(147; 49.7 %) of the potential DDI exhibited good 
scientific evidence availability while 116 (39.2%) 
showed a delayed onset (Table 3). Most (142; 53.4%) of 
the interactions were pharmacokinetic in mechanism. 
3.4 Drugs with major drug-drug interaction 
Digoxin and spironolactone (14.3%) are found to be the 
most encountered concurrently prescribed drugs with a 
good documentation. Drug interactions between RHZ 
and efavirnezas well as atorvastatin andwarfarin are 
interactions found to have an excellent evidence of 
documentation (table 4). 
Table 4: List of frequently prescribed treatment combinations having major potential drug -drug interaction 
 
List of drugs with Major DDI  
Frequency n (%) 
D
o
cu
m
e
n
ta
ti
o
n
  
T
y
p
e 
o
f 
D
D
I 
Expected effect 
frequency 
N=70 
 
percentage 
Digoxin+ Spironolactone  15 14.3 Good PKI Increasing the risk of digoxin 
toxicity 
Aspirin + Heparin 12 11.4 Fair PDI Increased risk of bleeding 
Cotrimoxazole + Fluconazole 10 9.5 Fair PDI Increased risk of cardiotoxicity 
Atorvastatin + Warfarin 5 4.7 Excellent PDI Increased risk of bleeding 
Azithromycin + Metronidazole 5 4.7 Fair PDI Increased risk of QT-interval 
prolongation and arrhythmias. 
Enalapril + Spironolactone  
 
5 4.7 Good PDI may result in hyperkalemia 
Aspirin + Warfarin 
 
5 4.7 Fair PDI Increased risk of bleeding 
Aspirin + Clopidogrel 
 
5 4.7 
 
Fair PDI Increased risk of bleeding 
RHZ + Efavirnez 5 4.7 Excellent PKI Decreased serum Efavirenz  
concentrations 
Metronidazole + Warfarin 5 4.7 Good PKI Increased level of warfarin 
Chloroquine + Ondansetron, 1 0.95 Fair PDI Increased risk of QT prolongation 
Ceftazidime + Warfarin  3 2.8 Good PDI Increased risk of bleeding 
Ciprofloxacin + Insulin 4 3.8 Fair PDI Enhanced effect of insulin 
Fluconazole + Gentamicin  3 2.8 Good Unknown Decreased level Gentamicin 
Ciprofloxacin + Metronidazole 4 3.8 Fair PDI Increased risk of arrhythmia 
RHZ + Acetaminophen 3 2.8 Excellent PKI Increased risk of hepatotoxicity 
Clopidogrel + Omeprazole  3 2.8 Excellent PKI Lesser effect of clopidogrel 
Carbamazepine + Tramadol 3 2.8 Fair PKI Decreased level and effect of 
tramadol 
 Haloperidol + Tramadol  3 2.8 Fair PDI Increased risk of CNS depression 
Dexamethasone + Efavirnez 1 0.95 Fair PKI Decreased level and effect of 
efavirenz 
Simvastatin + Warfarin 3 2.8 Excellent PKI Increased INR 
Carbamazepine + Simvastatin, 3 2.8 Good PKI Reduced simvastatin exposure 
DDI=Drug-drug interaction; PKI= Pharmacokinetic interaction; PDI= Pharmacodynamic interaction; RHZ=rifampicin+isoniazide 
and pyrazinamide 
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3.5 Association of DDI with predicting factors 
Univariate logistic regression analysis was done 
between independent and dependent variables. Table 
5 below shows that there is association of the occurrence 
of one or more potential DDIs with the number of 
medications prescribed per patient who took more than 
four medications [odds ratio (95% CI)=7.034 (2.130, 
11.089) and P=0.001], but other variables like sex,co-
morbidity  and age  have no association with potential 
DDIs.
  
Table 5: predicting factor of potential DDI in medical wards of SPHMMC, 2016(n=384) 
Variable Potential DDI P value OR(95%CI) 
yes no 
Sex 
Male  
Female  
 
88 
121 
 
105 
70 
0.321 
- 
0.540 
 
1.00 
4.650 (0.320–0.810) 
Age 
   15-24 
   25-44 
   45-64 
   ≥65 
 
29 
87 
54 
39 
 
 
28 
91 
42 
17 
0.078 
- 
0.561 
0.345 
0.07 
 
 
1.00 
0.538 (0.085, 3.409) 
0.718 (0.150, 3.442) 
0.563 (0.115, 2.747) 
Polypharmacy 
≤ 4  
≥5 
 
 
 
 
110 
99 
 
 
152 
23 
0.001 
- 
0.001 
  
1.00 
7.034 (2.130–11.089)∗ 
 
Co-morbidity 
Present 
Absent 
 
29 
180 
 
 
26 
149 
0.639 
- 
0.639 
 
1.000 
0.72(0.43,1.2) 
 
 
4. DISCUSSION  
The current study determined the prevalence of potential 
DDI in adult Patients admitted to medical wards. In a 
sample of 384 medication charts, the study revealedthat 
prevalence of potential DDIs was 54.30%. Although the 
methodology vary from those used in other studies, the 
result isin concordance with previously cited studies 
20-
22
, which reported prevalence potential DDIs with the 
range of 52.17% to 66%.  A prospective study conducted 
in the medication charts in medicine wards of Bangalore, 
India showed that 52.17% (n=230) of hospitalized 
Patients were exposed to 330 potential DDIs 
20
. 
Among the 296 DDIs identified, 2 (0.7%) of them were 
contraindicated combinations, 105(26.2%) were major, 
111 (42.6%) were moderate and 23 (8.6%) were minor 
interactions. The finding was comparable with Jimmy et 
al 
20
 in which prevalence major drug interaction was 
24.85%.The prevalence of moderate drug interaction in 
the current study, however,  is slightly higher than study 
done northern Ethiopia by Teka et al.,2016 
23 
. 
The clinical significance of potential DDIs in our study 
is superior in comparison to study done in Brazilian 
teaching hospital which revealed a 3.4% of major DDIs 
from a total 887 interacting combinations 
24
. Similarly, 
the clinical significance of current study is much higher 
than a study conducted in Indian tertiary care hospital 
which reported 0.14%, 3.6%, and 27.9% of 
contraindicated, major and moderate level of clinical 
significance, respectively 
25
. Thus, the current study is 
instrumental to make awareness on the dangerous 
potential interactions that could compromise the clinical 
outcome and pose adverse effect on patients. 
In this study, the most frequently prescribed major DDI 
in this study was concurrent use of digoxin with 
spironolactone. Concomitant use of digoxin and 
spironolactone may result in increased digoxin exposure 
andenhance the risk of digoxin toxicity 
26
. The second 
most common interaction identified were aspirin and 
heparin. Concomitant use of heparin, an anticoagulant, 
with an NSAID increases the risk of gastrointestinal 
bleeding due to the potential for decreased platelet 
function and decreased coagulation 
19
. However, the 
concurrent clinical use these two drugs might be 
inevitable. Therefore, close monitoring and evaluation of 
patient’s response is vital.  
In the present study, 74(27.7%), 87(32.6%) and 
39(14.6%) of Potential DDIs are identified to exhibit 
pharmacokinetic, pharmacodynamic and unknown 
mechanism of interactions, respectively. This is different 
from a similar study done in Addis Ababa, whereby 
49.8% of interaction mechanisms were pharmacokinetic 
type, while 44.6% and 5.6% of them were 
pharmacodynamic and unknown mechanisms, 
respectively
27
. This difference could be due to lack of 
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available treatment alternative in the study hospital for 
the high level of pharmacokinetic interaction
28
.  
There was significant association between polypharmacy 
(taking five drugs or more) and occurrence of drug- drug 
interaction (P<0.001)]. Different studies 
29-31
 also 
indentified that polyphatmacy increases the likelihood of 
potential DDIs occurrence. But, in the present study 
there was no association between age of patient and 
gender with the occurrence of drug-drug interaction. 
This study somewhat different from study conducted in 
Brazilian teaching hospital 
20
, which reported positive 
association of potential DDI with the patient’s gender 
and age. 
5. CONCLUSION AND RECOMMENDATION 
The findings of this study showed that the prevalence of 
potential DDIs among Patients admitted to medical 
wards was higher. This study also revealed presence of a 
significant association between DDI and number of 
medications prescribed per patient. Most of the 
interactions were of moderate-to-major severity. Major 
DDIs are considered clinically important and should be 
avoided by health care professionals. Health 
professionals should closely scrutinize drugs prescribed 
for patients. Identifying  and  preventing  potentially  
harmful  DDIs  is  a  vital  component  of  a  
pharmacist’s  mission which can be assisted by the 
presence  DDI software in the workstations of 
pharmacists. 
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